PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
25192889-7	2014	As a result, erlotinib is associated with a significant improvement in overall survival (P=0.0075, cohort 1; P=0.0372, cohort 2) and disease progression (P=0.6929, cohort 1; P=0.3347, cohort 2) in patients with reduced miRNA-21 expression.	Erlotinib Hydrochloride	13-22	microRNA 21	Homo sapiens	219-227	
26531758-8	2016	Moreover, miR-21, EGF and TGF-beta combined to markedly increase cancer cell invasion and migration, and this effect was blocked by the combination of erlotinib (an EGF receptor kinase inhibitor) and SB505124 (a type I TGF-beta receptor inhibitor).	Erlotinib Hydrochloride	151-160	microRNA 21	Homo sapiens	10-16	
25192889-11	2014	In conclusion, lung adenocarcinoma patients with reduced miRNA-21 expression exhibit longer overall survival and a poor response rate to erlotinib.	Erlotinib Hydrochloride	137-146	microRNA 21	Homo sapiens	57-65